iPierian Inc of California, which specialises in reprogramming induced pluripotent stem cells (iPSC) for treating Parkinson’s disease, spinal muscular atrophy and amyotrophic lateral sclerosis, has appointed Nancy E. Stagliano as its chief executive. She replaces Peter Van Vlasselaer, who will become executive chairman of the board.
Dr Stagliano was previously chief executive and co-founder of CytomX Therapeutic Inc which is developing protease-activated antibody therapeutics.
She obtained her PhD in Neuroscience from the University of Miami, followed by three years as an independently-funded research fellow at the Massachusetts General Hospital and Harvard Medical School, where she studied mechanisms of brain injury after stroke.
Copyright 2011 Evernow Publishing Ltd